Tepedelen B.E.Korkmaz M.Tatlisumak E.Uluer E.T.Ölmez E.Değerli İ.Soya E.İnan S.2024-07-222024-07-22201701634984http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15272Evidences about the preventive and therapeutic effects of boron compounds on cancer have been increasing in the last years. Although calcium fructoborate (CaFB) is used as a nutritional supplement, data about its preventive and therapeutic effects on neoplastic transformations are limited. In the present study, the various concentrations of CaFB were applied to the MDA-MB-231 metastatic breast cancer cell line. First, we examined the cytotoxic effect and IC50 value of CaFB by MTT assay. For the evaluation of the DNA damage, apoptosis and metastatic potential, expression levels of ATM, pATM, PARP, p53, p-p53, caspase-3, caspase-9, and VEGF were investigated by using immunoblotting and immunohistochemical methods. Cell viability was significantly reduced at 50 μM CaFB treatment. pATM, p-p53, and caspase-9 levels increased significantly in all groups; furthermore, there was approximately 12.5-, 2.4-, and 10.7-fold increase, respectively, for 100 μM CaFB treatment. ATM and p53 levels did not change with CaFB treatment, but PARP levels significantly 2.5-fold decreased. While VEGF immunoreactivity decreased in all groups, significant increase in caspase-3 immunoreactivity was observed only in the group treated with 50 μM CaFB (p < 0,001). Our results imply that CaFB may have therapeutic potential as well as preventive benefits in cancer. © 2016, Springer Science+Business Media New York.EnglishAnticarcinogenic AgentsBoratesBreast NeoplasmsCell Line, TumorDrug Screening Assays, AntitumorFemaleFructoseHumansNeoplasm ProteinsATM proteinboric acidcalcium fructoboratecaspase 3caspase 9DNAnicotinamide adenine dinucleotide adenosine diphosphate ribosyltransferasenutrition supplementprotein p53unclassified drugvasculotropinantineoplastic agentboric acidcalcium fructoboratefructosetumor proteinapoptosisArticlecell viabilitycontrolled studycytotoxicityDNA damagefemalehumanIC50immunoblottingimmunohistochemistryimmunoreactivityMDA-MB-231 cell linemetastatic breast cancerMTT assayprotein expressionanalogs and derivativesbreast tumordrug screeningmetabolismpathologytumor cell lineArticle10.1007/s12011-016-0918-6